8:06AM Rexahn Pharmaceuticals provides update on 2012 strategic goals; in continuing dialogue with a range of potential partners and continues new CEO search (RNN) 0.47 : Co provides update on 2012 strategic goals, co is in continuing dialogue with a range of potential partners, including out-licensing or co-development of the company's promising oncology assets and is continuing its new CEO search. Co is also continuing evaluation of options for building additional value in CNS program (Serdaxin and Zoraxel).
Market Data 
Markets 
AI
